Huadong Medicine’s HDM1005 Receives FDA Clearance for Heart Failure and Obesity Clinical Trial
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from...
Company
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for SHR-1501 Combo in Bladder Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading China-based pharmaceutical company, has announced that...
Sino Biopharmaceutical’s Benmelstobart Meets Primary Endpoint in Phase III NSCLC Study
Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biopharmaceutical company, has announced positive results from...
Hansoh Pharmaceutical Secures Global Licensing Deal with Merck for HS-10535
China’s Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a significant global license deal...
UCB’s Minzasolmin Fails to Meet Endpoints in ORCHESTRA Study for Early Parkinson’s
Belgium-based biopharmaceutical company UCB (EBR: UCB) has announced the disappointing results of the ORCHESTRA proof-of-concept...
HealthyWay Inc. Completes HKD 220 Million IPO on the Hong Kong Stock Exchange
China-based HealthyWay Inc. (HKG: 2587) has made a significant debut on the Hong Kong Stock...
Sino Biopharmaceutical and Sinopharm Group Collaborate to Expand Retail Pharmacy Network
In a significant move for China’s pharmaceutical industry, Sino Biopharmaceutical Ltd (HKG: 1177) and Sinopharm...
Everest Medicines’ Velsipity (Etrasimod) Receives First Prescription in Foshan under GBA Policy
Everest Medicines (HKG: 1952), a leading biopharmaceutical company based in China, has announced that its...
ImmuneOnco Biopharmaceuticals Initiates Phase Ib Study for Amulirafusp Alfa in NMOSD
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541), a China-based biopharmaceutical company, has announced the commencement of...
Henlius Biotech Joins Biosimilars Forum to Expand Global Biosimilars Access
Shanghai Henlius Biotech Inc. (HKG: 2696), a leading Chinese biopharmaceutical company, has announced its membership...
MicroPort CardioFlow Medtech’s VitaFlow Liberty Flex Receives NMPA Approval
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a prominent player in the medical device industry...
Lepu Scientech’s ScienCcrown TAVR System Earns NMPA Medical Device License
Lepu Scientech Medical Technology (Shanghai) Co., Ltd (HKG: 2291), a leading China-based medical technology company,...
Eli Lilly’s Kisunla Receives NMPA Approval for Early Alzheimer’s Disease Treatment
Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical corporation in the US, has announced...
BioNova Pharmaceuticals’ BN104 Receives Breakthrough Therapy Designation in China
The China’s Center for Drug Evaluation (CDE) website has indicated that BioNova Pharmaceuticals (Shanghai) Ltd.’s...
Evopoint Biosciences Submits Pre-NDA for Funobactam, Imipenem, and Cilastatin to NMPA
Suzhou-based Evopoint Biosciences Co., Ltd. has announced the submission of a Pre-NDA (New Drug Application)...
Xtalpi Inc. Partners with Gnosis Neurodynamics to Develop Neural Drug Screening Platform
Shenzhen-based QuantumPharm Inc., trading as Xtalpi Inc. (HKG: 2228), has announced a strategic partnership with...
GSK’s Blenrep and Star Pharma’s Topiramate Solution Target Priority Review in China
The China’s Center for Drug Evaluation (CDE) website has signaled that GlaxoSmithKline’s (GSK; NYSE: GSK)...
Sciwind Biosciences’ Ecnoglutide Accepted for Review by NMPA for Weight Management
Sciwind Biosciences Co., Ltd has received a significant boost as the National Medical Products Administration...
Blackstone and Bain Capital Submit Final Bids for Mitsubishi Tanabe Pharma
In a significant development in the alternative asset management sector, companies such as Blackstone and...
Everest Medicines’ Velsipity NDA for Ulcerative Colitis Accepted by China’s NMPA
China-based Everest Medicines (HKG: 1952) has announced that the National Medical Products Administration (NMPA) has...